Fluvastatin: a choice for COVID-19 associated mucormycosis management

Curr Med Chem. 2023 Jul 6. doi: 10.2174/0929867331666230706152616. Online ahead of print.ABSTRACTSARS-CoV-2 invades the respiratory tract epithelium and can result in systemic inflammation prior to an infection caused by either bacteria or fungus. COVID-19-associated mucormycosis (CAM) is a serious condition that can occur during the time of the disease due to increased administration of corticosteroids. Various studies have suggested that statins may improve clinical outcomes in COVID-19 patients. According to several preclinical reports, fluvastatin was shown to exert direct and indirect synergistic antifungal activity. Thus, fluvastatin could be considered a potential antifungal agent when no other option is available. Furthermore, in comparison with other statins, fluvastatin exhibits the fewest drug/drug interactions with anti-Mucorales azoles (e.g., isavuconazole and posaconazole), as well as with medicines that are used in solid organ transplant recipients (e.g., cyclosporine) and HIV-positive individuals (e.g., ritonavir); two groups of patients that have a higher risk of infection with Mucorales fungi following a SARS-CoV-2 infection.PMID:37415368 | DOI:10.2174/0929867331666230706152616
Source: Current Medicinal Chemistry - Category: Chemistry Authors: Source Type: research